Hydroxynidone
AssetAlso called Hydronidone, honginone, F 351
Pyridinone-based antifibrotic and anti-inflammatory small molecule
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial NCT07262333 is still running. Trial NCT07262333 updated in its registry on Aug 13, 2026. clinicaltrials.gov
Indications
1Chronic renal insufficiency
Phase 1, Recruiting, NCT07262333, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors9
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.